UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Blood, 2018-07, Vol.132 (1), p.40-48

2018

Volltextzugriff (PDF)

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

British journal of haematology, 2019-03, Vol.184 (5), p.744-752

2019

Volltextzugriff (PDF)

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

The lancet oncology, 2011-12, Vol.12 (13), p.1222-1228

2011

Volltextzugriff (PDF)

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4587-4594

2008

Volltextzugriff (PDF)

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Haematologica (Roma), 2016-08, Vol.101 (8), p.968-975

2016

Volltextzugriff (PDF)

Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia

PloS one, 2013-08, Vol.8 (8), p.e70352-e70352

2013

Volltextzugriff (PDF)

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2007-03, Vol.25 (9), p.1114-1120

2007

Volltextzugriff (PDF)

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Blood, 2016-05, Vol.127 (19), p.2310-2321

2016

Volltextzugriff (PDF)

Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma

Annals of hematology, 2022-02, Vol.101 (2), p.335-340

2022

Volltextzugriff (PDF)

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma

Journal of clinical oncology, 2018-10, Vol.36 (30), p.3015-3022

2018

Volltextzugriff (PDF)

Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study

Journal of clinical oncology, 2009-11, Vol.27 (32), p.5376-5382

2009

Volltextzugriff (PDF)

ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia

Clinical cancer research, 2007-09, Vol.13 (18), p.5295-5304

2007

Volltextzugriff (PDF)

Survival of subcutaneous panniculitis-like T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified: A propensity matched analysis of the Surveillance, Epidemiology and End Results database

Clinical lymphoma, myeloma and leukemia, 2016-07, Vol.16 (7), p.373-378

2016

Volltextzugriff (PDF)

Outcomes After Hematopoietic Stem-Cell Transplantation for Hematologic Malignancies in Patients With or Without Advance Care Planning

Journal of clinical oncology, 2007-12, Vol.25 (35), p.5643-5648

2007

Volltextzugriff (PDF)

Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?

Future oncology (London, England), 2022-01, Vol.18 (3), p.311-321

2022

Volltextzugriff (PDF)

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

British journal of haematology, 2020-05, Vol.189 (3), p.e86-e90

2020

Volltextzugriff (PDF)

Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study

British journal of haematology, 2023-07, Vol.202 (1), p.116-121

2023

Volltextzugriff (PDF)

Lymphomas with pseudo–double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations

Human pathology, 2018-10, Vol.80, p.192-200

2018

Volltextzugriff (PDF)

Angioimmunoblastic T-Cell Lymphoma Management

Seminars in hematology, 2014, Vol.51 (1), p.52-58

2014

Volltextzugriff (PDF)

Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia

American journal of hematology, 2016-11, Vol.91 (11), p.E468-E472

2016

Volltextzugriff (PDF)

Role of radiation therapy in primary mediastinal large B‐cell lymphoma in rituximab era: A US population‐based analysis

American journal of hematology, 2015-11, Vol.90 (11), p.1052-1054

2015

Volltextzugriff (PDF)

Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17 (9), p.569-574

2017

Volltextzugriff (PDF)

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

European journal of haematology, 2015-10, Vol.95 (4), p.361-364

2015

Volltextzugriff (PDF)

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Blood, 2008-02, Vol.111 (4), p.1848-1854

2008

Volltextzugriff (PDF)

High-Dose Therapy/Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Marginal Zone Non-Hodgkin Lymphoma

Clinical lymphoma, myeloma and leukemia, 2011-06, Vol.11 (3), p.253-256

2011

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(131)
Berichte
(2)

Sprache

Englisch
(133)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(54)
Humans
(53)
Oncology
(36)
Adult
(34)
Female
(34)
Male
(34)
Middle Aged
(33)
Aged
(28)
Hematology
(25)
Treatment Outcome
(19)
Aged, 80 And Over
(13)
Hematology, Oncology And Palliative Medicine
(13)
Young Adult
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Prognosis
(10)
Adolescent
(9)
Biological And Medical Sciences
(9)
Lymphoma
(9)
Medical Sciences
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non‐Hodgkin lymphoma

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL

Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma

Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study

ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38–Expressing B-Cell Chronic Lymphocytic Leukemia

Survival of subcutaneous panniculitis-like T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified: A propensity matched analysis of the Surveillance, Epidemiology and End Results database

Outcomes After Hematopoietic Stem-Cell Transplantation for Hematologic Malignancies in Patients With or Without Advance Care Planning

Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?

Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study

Lymphomas with pseudo–double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations

Angioimmunoblastic T-Cell Lymphoma Management

Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia

Role of radiation therapy in primary mediastinal large B‐cell lymphoma in rituximab era: A US population‐based analysis

Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

High-Dose Therapy/Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Marginal Zone Non-Hodgkin Lymphoma

Suchergebnisse filtern